Market Overview

BTIG Says Buy The Dip In Medtronic

BTIG Says Buy The Dip In Medtronic

Shares of medical technology company Medtronic PLC (NYSE: MDT) were flirting with the $100 per share mark for parts of 2018, but have since come down to a level that should be taken advantage of by investors, according to BTIG.

The Analyst

Analyst Sean Lavin upgraded Medtronic from Neutral to Buy with a new $100 price target.

The Thesis

During the JPM Healthcare conference last week in San Francisco, BTIG spent time with Medtronic CEO Omar Ishrak and CFO Karen Parkill.

Lavin's primary takeaway was that the executives appeared to be "very conservative" on the impact of worries about paclitaxel and higher mortality signals. The company's management feels "very confident" its devices are safe and has the necessary data to back up the claim, the analyst said. 

During the conference, Medtronic lowered its 2019 outlook due to a slowdown in the DCB market from paclitaxel concerns and changes to the LVAD market, Lavin said. This creates a scenario where Medtronic should be able to at the very least match its guidance or even beat it, he said. 

Beyond 2019, the company boasts a "broad and rich" pipeline for fiscal 2020 that can help generate at least 4-percent top-line growth in spine, neurovascular, leadless pacing and diabetes, the analyst said. The Street will also view a robotics launch favorably, although the company's ambitions are not yet clear, as such a move could impact surgical margins, he said. 

Price Action

Medtronic shares were up 1.75 percent at $86.22 at the time of publication Tuesday. 

Related Links:

JPMorgan Upgrades Medtronic After String Of Outperformances

BofA: Medtronic's Growth 'Should Continue To Surprise'

Photo courtesy of Medtronic. 

Latest Ratings for MDT

Feb 2019CitigroupMaintainsNeutralNeutral
Jan 2019BTIG ResearchUpgradesNeutralBuy
Jan 2019BarclaysMaintainsOverweightOverweight

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: btig Medical TechnologyAnalyst Color News Health Care Events Analyst Ratings General Best of Benzinga


Related Articles (MDT)

View Comments and Join the Discussion!

Latest Ratings

DRIBank of AmericaReiterates130.0
PVACNorthland SecuritiesUpgrades0.0
NKEWells FargoMaintains80.0
DRIWells FargoMaintains120.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Trader Essentials
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

First China Sales Decline In 28 Years Puts Automakers In A Tight Spot

Zacks Free Lunch: The Q4 Earnings Story So Far